
Spruce Biosciences, Inc. (NASDAQ:SPRB – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for Spruce Biosciences in a research note issued to investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($29.01) per share for the year, down from their prior forecast of ($23.32). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($28.15) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2026 earnings at ($5.71) EPS, Q1 2027 earnings at ($4.35) EPS, Q2 2027 earnings at ($3.96) EPS, Q3 2027 earnings at ($2.58) EPS, Q4 2027 earnings at $0.32 EPS and FY2027 earnings at ($10.38) EPS.
Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($8.51) EPS for the quarter, missing analysts’ consensus estimates of ($5.68) by ($2.83).
Several other equities research analysts have also recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Spruce Biosciences in a research report on Thursday. Guggenheim restated a “buy” rating and set a $104.00 target price (down from $123.00) on shares of Spruce Biosciences in a research report on Monday, August 17th. Lake Street Capital started coverage on shares of Spruce Biosciences in a research note on Thursday, September 17th. They set a “buy” rating and a $149.00 target price for the company. Wall Street Zen raised shares of Spruce Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Citizens Jmp set a $143.00 price target on shares of Spruce Biosciences in a report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $158.22.
Check Out Our Latest Stock Report on Spruce Biosciences
Spruce Biosciences Trading Down 2.4%
Shares of SPRB opened at $42.25 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.83 and a quick ratio of 9.23. Spruce Biosciences has a 1 year low of $38.06 and a 1 year high of $127.90. The company has a 50 day simple moving average of $46.91 and a two-hundred day simple moving average of $54.09. The firm has a market cap of $121.43 million, a P/E ratio of -1.25 and a beta of 3.57.
Institutional Trading of Spruce Biosciences
A number of large investors have recently added to or reduced their stakes in the company. SkyView Investment Advisors LLC bought a new position in shares of Spruce Biosciences during the 2nd quarter valued at approximately $162,000. Pale Fire Capital SE purchased a new position in shares of Spruce Biosciences in the second quarter valued at $206,000. AWM Investment Company Inc. bought a new stake in Spruce Biosciences in the second quarter worth $7,937,000. Bank of New York Mellon Corp bought a new stake in Spruce Biosciences in the second quarter worth $366,000. Finally, Stempoint Capital LP bought a new stake in Spruce Biosciences in the first quarter worth $416,000. Institutional investors own 91.71% of the company’s stock.
Spruce Biosciences Company Profile
Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. The U.S.-based company has concentrated on conditions with limited treatment options and has advanced oral drug candidates through clinical development. Its lead investigational candidate, tildacerfont, is a corticotropin-releasing factor type 1 receptor antagonist that Spruce studied for congenital adrenal hyperplasia, a rare disorder affecting hormone production. The company also evaluated the candidate for other endocrine conditions, including polycystic ovary syndrome.
Read More
- Five stocks we like better than Spruce Biosciences
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
